Results 81 to 90 of about 7,465 (248)

66Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?

Molecules, 2018
Emerging interest in extending the plasma half-life of small molecule radioligands warrants a consideration of the appropriate radionuclide for PET imaging at longer time points (>8 h). Among candidate positron-emitting radionuclides, 66Ga (t1/2 = 9.5
Alejandro Amor-Coarasa, James M. Kelly, Shashikanth Ponnala, Anastasia Nikolopoulou, Clarence Williams, John W. Babich   +5 more
doaj   +1 more source

Precise activity measurements of medical radionuclides using an ionization chamber: a case study with Terbium-161

EJNMMI Physics, 2022
Background 161Tb draws an increasing interest in nuclear medicine for therapeutic applications. More than 99% of the emitted gamma and X-rays of 161Tb have an energy below 100 keV.
Frédéric Juget, Zeynep Talip, Youcef Nedjadi, M. Teresa Durán, Pascal V. Grundler, Jan Rijn Zeevaart, Nicholas P. van der Meulen, Claude Bailat   +7 more
doaj   +1 more source

Quantitative studies in radiopharmaceutical science. Final report, January 1, 1993--December 31, 1993 [PDF]

, 1996
This report briefly summarizes published research at the University of Chicago in the area of quantitative studies in radiopharmaceutical science covering radiochemistry and PET/MRI imaging.
Cooper, M., Beck, R.N.
openaire   +2 more sources

Cyclotron-Based Production of ⁶⁷Cu for Radionuclide Theranostics via the ⁷⁰Zn(p,α)⁶⁷Cu Reaction

, 2023
Theranostic matched pairs of radionuclides have aroused interest during the last couple of years, and in that sense, copper is one element that has a lot to offer, and although 61Cu and 64Cu are slowly being established as diagnostic radionuclides for ...
Klaus Kopka, Martin Kreller, Torsten Kniess, Santiago Andrés Brühlmann, Hans-Jürgen Pietzsch, Falco Reissig, Martin Walther   +6 more
core   +1 more source

Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson's Disease

Annals of Neurology, EarlyView.
Objective Positive α‐synuclein seed amplification assay (SAA) is a biomarker found in most people with Parkinson's disease (PD). We explored if free‐water (FW) imaging detects microstructural differences in the brains of patients with early PD with SAA+ or SAA– status.
Shannon Y. Chiu, Wei‐en Wang, Robin Chen, Jesse C. DeSimone, Derek B. Archer, Charles H. Adler, Shyamal H. Mehta, Sara R. Dresler, Melissa J. Armstrong, Nikolaus McFarland, Michael Okun, David E. Vaillancourt, Parkinson's Progression Markers Initiative, Neha Prakash, Tanya Simuni, Nabila Dahodwala, Caroline Tanner, Lana Chahine, Brit Mollenhauer, Anat Mirelman, Roy Alcalay; Katherine Leaver, Marie Saint‐Hilaire, Ruth Schneider, Christopher Tarolli, Werner Poewe, Aleksandar Videnovic, David Standaert, Marissa Dean, Sonja Jonsdottir, Rejko Krueger, Claire Pauly, Stewart Factor, Penelope Hogarth, Robert Hauser, Amy Amara, Michelle Fullard, Cyrus Zabetian, Hubert Fernandez, Kathrin Brockmann, Isabel Wurster, Yen Tai, Paolo Barone, Marina Picillo, Stuart Isaacson, Alberto Espay, Eduardo Tolosa, Javier Ruiz Martinez, Leonidas Stefanis, Kelvin Chou, Lorraine Kalia, Connie Marras, David Grimes, Tiago Mestre, Rajesh Pahwa, Mark Lew, Holly Shill, Shyamal Mehta, Giulietta Riboldi, Nikolaus McFarland, Ron Postuma, Zoltan Mari, David Ledingham, Nicola Pavese, Michele Hu, Norbert Brueggemann, Christine Klein, Bastiaan Bloem, Cristina Simonet, Alastair Noyce, Anette Janzen, David Pedrosa, Wolfgang Oertel, Njideka Okubadejo, David Shprecher, Arjun Tarakad, Emile Moukheiber, Joy Antala, Carla Aranda, Karen Williams, Sophia Melton, Karina Benson, Ashwini Ramachandran, Danielle Potts, Grace LaMoure, Ritikha Vengadesh, Ryan Manzler, Jaime Heller, Primi Ranola, Farah Kausar, Sherri Mosovsky, Diana Willeke, Elizabeth Kalinkara Gomez, Janelle Rodriguez, Nobuko Kemmotsu, May Eshel, Deborah Raymond, Abigail Desrosiers, Raymond James, Lauren Jackson, Iris Egner, Wesley Schlett, Courtney Blair, Lauren Ruffrage, Berenice Sevilla, Barbara Sommerfeld, Dustin Le, Erica Botting, Gabriella Mazur, Daniele Derlein, Ying Liu, Ciera Cobb, Olivia Masiewicz, Jennifer Mule, Michael Morsillo, Ella Hilt, Lisbeth Pennente, Bobbie Stubbeman, Alicia Garrido, Valeria Ravasi, Ioana Croitoru, Christos Koros, Nikolas Papagiannakis, Frank Ferrari, Mengyu Zheng, Shawna Reddie, Alicia Alejandra, Andrea Gray, Alejandra Valenzuela, Caitlin Goodman, Sara Dresler, Neil Santos, Fahrial Esha, Kyle Rizer, Nadine Zablith, Liliana Dumitrescu, Debra Galley, Victoria Kate Foster, Jamil Razzaque, Madita Grümmer, Yara Krasowski, Elisabeth Sittig, Oluwadamilola Ojo, Kelly Clark, Rory Mahabir, Kori Ribb, Shamera Willoughby   +145 more
wiley   +1 more source

Radiosynthesis and evaluation of an 18F–labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma

EJNMMI Radiopharmacy and Chemistry, 2018
Background Analogues of exendin-4 have been radiolabeled for imaging the glucagon-like peptide type 1 receptors (GLP-1R) which are overexpressed in insulinoma. The aim of this research was to synthesize an 18F–labeled silicon containing exendin-4 peptide
Lukas O. Dialer, Andreas Jodal, Roger Schibli, Simon M. Ametamey, Martin Béhé   +4 more
doaj   +1 more source

Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers

Scientific Reports, 2023
The heterogenous treatment response of tumor cells limits the effectiveness of cancer therapy. While this heterogeneity has been linked to cell-to-cell variability within the complex tumor microenvironment, a quantitative biomarker that identifies and ...
Tina Pekeč, Saradha Venkatachalapathy, Anne R. Shim, Daniel Paysan, Michal Grzmil, Roger Schibli, Martin Béhé, G. V. Shivashankar   +7 more
doaj   +1 more source

PET Imaging in Bladder Cancer: An Update and Future Direction

, 2023
Molecular imaging with positron emission tomography is a powerful tool in bladder cancer management. In this review, we aim to address the current place of the PET imaging in bladder cancer care and offer perspectives on potential future ...
Jules Zhang-Yin, Etienne Marchal, Antoine Girard, Thierry Lebret, Marine Uhl, Marie Homo Seban, Marc Bertaux   +6 more
core   +1 more source

Technology Transfer of O-(2-[18F] Fluoroethyl)-L-Tyrosine (IASOglio®) Radiopharmaceutical

Background/Objectives: Gliomas, including the most aggressive subtype—glioblastoma multiforme, are brain tumors with an unfavorable prognosis and high mortality. Early diagnosis is essential to improve treatment efficacy.
Alessia Danti, Michela Poli, Anna Notaro, Mauro Telleschi, Alessandro Zega, Antonio Fiore, Lucie Plougastel, Salvatore Limpido, Mauro Quaglierini, Letizia Guiducci   +9 more
core   +1 more source

Fully Automated GMP-Compliant Synthesis of [¹⁸F]FE-PE2I

, 2021
In the struggle to understand and accurately diagnose Parkinson′s disease, radiopharmaceuticals and medical imaging techniques have played a major role. By being able to image and quantify the dopamine transporter density, noninvasive diagnostic imaging ...
Matthias Manfred Herth, Klas Bratteby, Erlandsson, Maria, Petersen, Ida Nymann, Madsen, Jacob, Ida Nymann Petersen, Lehel, Szabolcs, Herth, Matthias Manfred, Szabolcs Lehel, Bratteby, Klas, Charlotte Lund Denholt, Maria Erlandsson, Jacob Madsen, Ohlsson, Tomas, Nic Gillings, Gillings, Nic, Tomas Ohlsson, Denholt, Charlotte Lund   +17 more
core   +1 more source